Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer
Min Liu, … , Xiang Zhang, Jun Yan
Min Liu, … , Xiang Zhang, Jun Yan
Published January 16, 2020
Citation Information: J Clin Invest. 2020;130(4):2081-2096. https://doi.org/10.1172/JCI131335.
View: Text | PDF
Research Article Immunology

Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer

  • Text
  • PDF
Abstract

Macrophages have been linked to tumor initiation, progression, metastasis, and treatment resistance. However, the transcriptional regulation of macrophages driving the protumor function remains elusive. Here, we demonstrate that the transcription factor c-Maf is a critical controller for immunosuppressive macrophage polarization and function in cancer. c-Maf controls many M2-related genes and has direct binding sites within a conserved noncoding sequence of the Csf-1r gene and promotes M2-like macrophage–mediated T cell suppression and tumor progression. c-Maf also serves as a metabolic checkpoint regulating the TCA cycle and UDP-GlcNAc biosynthesis, thus promoting M2-like macrophage polarization and activation. Additionally, c-Maf is highly expressed in tumor-associated macrophages (TAMs) and regulates TAM immunosuppressive function. Deletion of c-Maf specifically in myeloid cells results in reduced tumor burden with enhanced antitumor T cell immunity. Inhibition of c-Maf partly overcomes resistance to anti–PD-1 therapy in a subcutaneous LLC tumor model. Similarly, c-Maf is expressed in human M2 and tumor-infiltrating macrophages/monocytes as well as circulating monocytes of human non–small cell lung carcinoma (NSCLC) patients and critically regulates their immunosuppressive activity. The natural compound β-glucan downregulates c-Maf expression on macrophages, leading to enhanced antitumor immunity in mice. These findings establish a paradigm for immunosuppressive macrophage polarization and transcriptional regulation by c-Maf and suggest that c-Maf is a potential target for effective tumor immunotherapy.

Authors

Min Liu, Zan Tong, Chuanlin Ding, Fengling Luo, Shouzhen Wu, Caijun Wu, Sabrin Albeituni, Liqing He, Xiaoling Hu, David Tieri, Eric C. Rouchka, Michito Hamada, Satoru Takahashi, Andrew A. Gibb, Goetz Kloecker, Huang-ge Zhang, Michael Bousamra II, Bradford G. Hill, Xiang Zhang, Jun Yan

×

Figure 9

WGP treatment downregulates c-Maf expression in human M2-like macrophages and circulating monocytes from NSCLC patients.

Options: View larger image (or click on image) Download as PowerPoint
WGP treatment downregulates c-Maf expression in human M2-like macrophage...
(A) Polarized human M2-like macrophages from heathy donor monocytes were treated with yeast whole β-glucan particles (WGP, 150 μg/mL) for 24 hours and c-Maf expression was determined by flow cytometry and WB analysis. The c-Maf mRNA expression levels in polarized M2-like macrophages (n = 4 donors) treated with WGP for 24 hours were also determined by qPCR analysis. *P < 0.05 by 2-tailed, unpaired t test. (B) Polarized human M2-like macrophages were treated with WGP (150 μg/mL) for 24 hours and the mRNA expression levels of indicated genes were determined by qPCR analysis. *P < 0.05, ***P < 0.001, ****P < 0.0001 by 2-tailed, unpaired t test. (C and D) PBMCs from NSCLC patients (n = 15) were treated with WGP in vitro for 24 hours. Representative histogram of c-Maf expression and summarized data for both CD14hiCD16+/lo (P1, C) and CD14dimCD16+ (P2, D) populations are shown. **P < 0.01; ****P < 0.0001 by 2-tailed, paired t test. IsoAb, isotype antibody. (E) PBMCs from NSCLC patients (n = 16) before or after oral WGP administration were stained for CD14 and CD16. Representative dot plots and summarized frequencies of CD14hiCD16+/lo (P1) and CD14dimCD16+ (P2) populations are shown. *P < 0.05 by 2-tailed, paired t test. (F) CD14hiCD16+/lo (P1) and CD14dimCD16+ (P2) populations from PBMCs of NSCLC patients treated before and after WGP were sorted. The mRNA expression levels of c-MAF, TNFA, and IL10 were determined by qPCR analysis. Data are shown as mean ± SEM. *P < 0.05 by 2-tailed, paired t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts